However, among patients with valvular heart disease, diabetes was associated with increased fasting plasma GLP‐1 level, regardless of glucose-lowering therapy and valve phenotype, which possibly indicated a compensatory mechanism (Krizhanovskii et al., 2017). The gene discussed is GLP1R; the disease is diabetes mellitus.